Physician profile
Margaret E Johnson
NPI 1073698692
$2,083.52
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $283 · 2023: $1,008 · 2024: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.12 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $283.87 | 2022-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $257.84 | 2023-2024 | Auvelity, Sunosi |
| Abbvie INC. | $241.67 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.06 | 2022-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $174.73 | 2022-2024 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $128.28 | 2023-2024 | Xelstrym, Secuado |
| Almatica Pharma LLC | $123.88 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $108.76 | 2023 | Quviviq |
| Corium, LLC | $91.88 | 2022-2024 | Azstarys |
| Alkermes, INC. | $90.01 | 2022-2024 | Aristada, Lybalvi |
| Tris Pharma INC | $84.36 | 2023-2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $50.21 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $49.56 | 2022 | |
| Biogen, INC. | $23.39 | 2024 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $21.85 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $21.60 | 2024 | |
| Bausch Health US, LLC | $21.51 | 2023 | Aplenzin |
| Janssen Pharmaceuticals, INC | $21.37 | 2023 | Spravato |
| Owp Pharmaceuticals, INC. | $20.91 | 2024 | Subvenite |
| Biohaven Pharmaceutical Holding Company LTD. | $20.31 | 2022 | |
| Avion Pharmaceuticals | $20.26 | 2023 | NP Thyroid 60 |
| Neos Therapeutics, LP | $15.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.